SCHEMBL720449

SCHEMBL720449

Cc1nc2cc(Cl)c(-c3ccc(-c4ccc(C(N)=O)c(Cl)c4)s3)cc2o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
PRF1 P14222 2/20 0.37
PDK2 Q15119 1/20 0.35
FPR2 P25090 2/20 0.34
GPR52 Q9Y2T5 4/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PGR P06401 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
JAK2 O60674 2/20 0.33
S1PR1 P21453 1/20 0.33
POLB P06746 1/20 0.33
BTK Q06187 1/20 0.32
PIK3CD O00329 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722988 0.91 FPR2 (0.39) PRF1FPR2GPR52SMN1; SMN2KDM4E
SCHEMBL724533 0.82 FPR2 (0.37) FPR2GAAL3MBTL1SMN1; SMN2KDM4E
SCHEMBL1701281 0.72 GAA (0.41) GAAL3MBTL1PIK3CDPIK3CA
SCHEMBL29642114 0.69 STIM1 (0.63) MAPTRAB9AKMT2A
SCHEMBL10201121 0.69 STIM1 (0.63) MAPTRAB9AKMT2A
SCHEMBL2592415 0.69 GAA (0.45) GAAL3MBTL1SMN1; SMN2KDM4EMAPT
SCHEMBL722510 0.69 SNCA (0.49) MKNK1MKNK2PRF1PDK2KDM4E
SCHEMBL10201122 0.67 IL2 (0.57) GAASMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL29642097 0.67 IL2 (0.57) GAASMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL724411 0.67 STIM1 (0.48) PRF1GPR52RAB9AKMT2AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336738-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2019-07-02 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
EP-2609095-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2013-07-03 EP disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed
WO-2012027710-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336738-B2 Compounds that modulate intracellular calcium ORAI1, SARAF, RYR2 MKNK1 1391/4885MKNK2 1414/4885PRF1 2531/4885
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MKNK1 1391/4885MKNK2 1414/4885PRF1 2531/4885
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MKNK1 1391/4885MKNK2 1414/4885PRF1 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.